Syndromes of neurodegeneration with brain iron accumulation (NBIA): An update on clinical presentations, histological and genetic underpinnings, and treatment considerations

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 42-53

  Schneider, Susanne A ^a,b,c   Hardy, John ^b   Bhatia, Kailash P ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Iron; NBIA; PKAN; PLA2G6

Indexed keywords

CERULOPLASMIN; FERRITIN; IRON; PANTOTHENATE KINASE 2; PANTOTHENIC ACID; PHOSPHOLIPASE A2 GROUP VI;

ACERULOPLASMINEMIA; AUTOSOMAL RECESSIVE DISORDER; BRAIN DEPTH STIMULATION; CEREBELLUM ATROPHY; DEMENTIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FRIEDREICH ATAXIA; GAIT DISORDER; GENE MUTATION; GLOBUS PALLIDUS; HEREDITARY MOTOR SENSORY NEUROPATHY; KUFOR RAKEB DISEASE; MANNOSIDOSIS; NEUROAXONAL DYSTROPHY; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROFERRITINOPATHY; NEURONAL CEROID LIPOFUSCINOSIS; OCULOMOTOR NERVE DISEASE; ONSET AGE; PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION; PARKINSONISM; PRIORITY JOURNAL; RETINOPATHY; REVIEW;

BRAIN; CERAMIDES; CERULOPLASMIN; GROUP VI PHOSPHOLIPASES A2; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IRON; IRON METABOLISM DISORDERS; LEWY BODIES; NEUROAXONAL DYSTROPHIES; NEURODEGENERATIVE DISEASES; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 84855962257     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23971     Document Type: Review

References (107)

1. Perls M. Nachweis von Eisenoxyd in gewissen Pigmenten [Demonstration of iron oxide in certain pigments]. Virchow's Arch Pathol Anat Physiol Klin Med 1867; 39: 48.
2. Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci 2011; 303: 1-12.
3. Koeppen AH, Morral JA, McComb RD, et al. The neuropathology of late-onset Friedreich's ataxia. Cerebellum 2011; 10: 96-103.
4. Spatz H. Uber den Eisennachweis im Gehirn, besonders in Zentren des extrpyramidal-motorischen Systems [On the visualization of iron in the brain, especially in the centers of the extrapyramidal motor system]. Z Ges Neurol Psychiat 1922; 77: 390.
5. Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed 2004; 17: 433-445.
6. Hallervorden J, Spatz H. Eigenartige Erkrankung im extrapyramidalen System mit besonderer Beteiligung des Globus pallidus und der Substantia nigra.: Ein Beitrag zu den Beziehungen zwischen diesen beiden Zentren. Z Ges Neurol Psychiat 1922; 254-302.
7. Cowen D, Olmstead EV. Infantile neuroaxonal dystrophy. J Neuropathol Exp Neurol 1963; 22: 175-236.
8. Shevell MI, Peiffer J. Julius Hallervorden's wartime activities: implications for science under dictatorship. Pediatr Neurol 2001; 25: 162-165.
9. Stankiewicz J, Panter SS, Neema M et al. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007; 4: 371-386.
10. Gregory A, Hayflick S. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009; 46: 73-80.
11. Hayflick SJ. Neurodegeneration with brain iron accumulation: from genes to pathogenesis. Semin Pediatr Neurol 2006; 13: 182-185.
12. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003; 348: 33-40.
13. Schneider SA, Aggarwal A, Bhatt M, et al. Severe tongue protrusion dystonia: clinical syndromes and possible treatment. Neurology 2006; 67: 940-943.
14. Marelli C, Piacentini S, Garavaglia B, et al. Clinical and neuropsychological correlates in two brothers with pantothenate kinase-associated neurodegeneration. Mov Disord 2005; 20: 208-212.
15. Egan RA, Weleber RG, Hogarth P, et al. Neuro-ophthalmologic and electroretinographic findings in pantothenate kinase-associated neurodegeneration (formerly Hallervorden-Spatz syndrome). Am J Ophthalmol 2005; 140: 267-274.
16. Bozi M, Matarin M, Theocharis I, et al. A patient with pantothenate kinase-associated neurodegeneration and supranuclear gaze palsy. Clin Neurol Neurosurg 2009; 111: 688-690.
17. Antonini A, Goldwurm S, Benti R, et al. Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. Mov Disord 2006; 21: 417-418.
18. Aggarwal A, Schneider SA, Houlden H, et al. Indian-subcontinent NBIA: unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms. Mov Disord 2010; 25: 1424-1431.
19. Yoon WT, Lee WY, Shin HY, et al. Novel PANK2 gene mutations in korean patient with pantothenate kinase-associated neurodegeneration presenting unilateral dystonic tremor. Mov Disord 2010; 25: 245-247.
20. Chung SJ, Lee JH, Lee MC, et al. Focal hand dystonia in a patient with PANK2 mutation. Mov Disord 2008; 23: 466-468
21. Fantini ML, Cossu G, Molari A et al. Sleep in genetically confirmed pantothenate kinase-associated neurodegeneration: a video-polysomnographic study. Parkinsons Dis 2010; 2010: 342834.
22. Awasthi R, Gupta RK, Trivedi R, et al. Diffusion tensor MR imaging in children with pantothenate kinase-associated neurodegeneration with brain iron accumulation and their siblings. AJNR Am J Neuroradiol 2010; 31: 442-447.
23. Hayflick SJ, Penzien JM, Michl W, et al. Cranial MRI changes may precede symptoms in Hallervorden-Spatz syndrome. Pediatr Neurol 2001; 25: 166-169.
24. Cossu G, Cella C, Melis M, et al. [123I]FP-CIT SPECT findings in two patients with Hallervorden-Spatz disease with homozygous mutation in PANK2 gene. Neurology 2005; 64: 167-168.
25. Hermann W, Barthel H, Reuter M, et al. [Hallervorden-Spatz disease: findings in the nigrostriatal system]. Nervenarzt 2000; 71: 660-665.
26. Doi H, Koyano S, Miyatake S, et al. Siblings with the adult-onset slowly progressive type of pantothenate kinase-associated neurodegeneration and a novel mutation, Ile346Ser, in PANK2: clinical features and (99m)Tc-ECD brain perfusion SPECT findings. J Neurol Sci 2010; 290: 172-176.
27. Kruer MC, Hiken M, Gregory A, et al. Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 2011; 134: 947-958.
28. Saito Y, Kawai M, Inoue K, et al. Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci 2000; 177: 48-59.
29. Wakabayashi K, Fukushima T, Koide R, et al. Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and Lewy body pathology. Acta Neuropathol 2000; 99: 331-336.
30. Neumann M, Adler S, Schluter O, et al. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol 2000; 100: 568-574.
31. Galvin JE, Giasson B, Hurtig HI, et al. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am J Pathol 2000; 157: 361-368.
32. Williamson K, Sima AA, Curry B, et al. Neuroaxonal dystrophy in young adults: a clinicopathological study of two unrelated cases. Ann Neurol 1982; 11: 335-343.
33. Eidelberg D, Sotrel A, Joachim C, et al. Adult onset Hallervorden-Spatz disease with neurofibrillary pathology. A discrete clinicopathological entity. Brain 1987; 110: 993-1013.
34. Hartig MB, Hortnagel K, Garavaglia B, et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006; 59: 248-256.
35. Kotzbauer PT, Truax AC, Trojanowski JQ et al. Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci 2005; 25: 689-698.
36. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795.
37. Poli M, Derosas M, Luscieti S, et al. Pantothenate kinase-2 (Pank2) silencing causes cell growth reduction, cell-specific ferroportin upregulation and iron deregulation. Neurobiol Dis 2010; 39: 204-210.
38. Castelnau P, Cif L, Valente EM, et al. Pallidal stimulation improves pantothenate kinase-associated neurodegeneration. Ann Neurol 2005; 57: 738-741.
39. Mikati MA, Yehya A, Darwish H, et al. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. Eur J Paediatr Neurol 2009; 13: 61-64.
40. Krause M, Fogel W, Tronnier V, et al. Long-term benefit to pallidal deep brain stimulation in a case of dystonia secondary to pantothenate kinase-associated neurodegeneration. Mov Disord 2006; 21: 2255-2257.
41. Szumowski J, Bas E, Gaarder K, et al. Measurement of brain iron distribution in Hallevorden-Spatz syndrome. J Magn Reson Imaging 2010; 31: 482-489.
42. Timmermann L, Pauls KA, Wieland K, et al. Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 2010; 133: 701-712.
43. Mylius V, Gerstner A, Peters M, et al. Low-frequency rTMS of the premotor cortex reduces complex movement patterns in a patient with pantothenate kinase-associated neurodegenerative disease (PKAN). Neurophysiol Clin 2009; 39: 27-30.
44. Rana A, Seinen E, Siudeja K, et al. Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration. Proc Natl Acad Sci U S A 2010; 107: 6988-6993.
45. Wu Z, Li C, Lv S, et al. Pantothenate kinase-associated neurodegeneration: insights from a Drosophila model. Hum Mol Genet 2009; 18: 3659-3672.
46. Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 2006; 38: 752-754.
47. Paisan-Ruiz C, Bhatia KP, Li A, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009; 65: 19-23.
48. Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009; 46: 73-80.
49. Paisan-Ruiz C, Li A, Schneider SA, et al. Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 2010 [Epub ahead of print].
50. Malik I, Turk J, Mancuso DJ, et al. Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations. Am J Pathol 2008; 172: 406-416.
51. Adibhatla RM, Hatcher JF. Phospholipase A(2): reactive oxygen species, and lipid peroxidation in CNS pathologies. BMB Rep 2008; 41: 560-567.
52. Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2010; 12: 125-169.
53. Engel LA, Jing Z, O'Brien DE et al. Catalytic function of PLA2G6 is impaired by mutations associated with Infantile Neuroaxonal Dystrophy but not Dystonia-Parkinsonism. PLoS ONE 2011; 5: e12897.
54. Vinters H, Farrell M, Mischel P, et al. Diagnostic Neuropathology. New York: Marcel Dekker Incorporated; 1998: 502.
55. Gregory A, Westaway SK, Holm IE, et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008; 71: 1402-1409.
56. Kruer MC, Paisan-Ruiz C, Boddaert N et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol. 2010; 68: 610-618.
57. Schneider SA, Bhatia KP. Three faces of the same gene: FA2H links neurodegeneration with brain iron accumulation, leukodystrophies, and hereditary spastic paraplegias. Ann Neurol 2010; 68: 575-577.
58. Najim al-Din AS, Wriekat A, Mubaidin A, et al. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994; 89: 347-352.
59. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38: 1184-1191.
60. Machner B, Sprenger A, Behrens MI, et al. Eye movement disorders in ATP13A2 mutation carriers (PARK9). Mov Disord 2010; 25: 2687-2689.
61. Di Fonzo A, Chien HF, Socal M, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007; 68: 1557-1562
62. Williams DR, Hadeed A, al Din AS, et al. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005; 20: 1264-1271.
63. Behrens MI, Bruggemann N, Chana P, et al. Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations. Mov Disord 2010; 25: 1929-1937.
64. Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010; 25: 979-984.
65. Bruggemann N, Hagenah J, Reetz K, et al. Recessively inherited parkinsonism: effect of ATP13A2 mutations on the clinical and neuroimaging phenotype. Arch Neurol 2010; 67: 1357-1363.
66. Chien HF, Bonifati V, Barbosa ER. ATP13A2-related neurodegeneration (PARK9) without evidence of brain iron accumulation. Mov Disord 2011; 26164-1365.
67. Zittel S, Kroeger T, Baeumer T, et al. Abnormal interhemispheric interactions in ATP13A2 mutation carriers: a TMS study. 14th Annual Meeting of the German Society of Neurogenetics, P3, 2008.
68. Paisan-Ruiz C, Guevara R, Federoff M, et al. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord 2010; 25: 1791-1800
69. Park JS, Mehta P, Cooper AA, et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset Parkinsonism Hum Mutat 2011; 32: 956-964.
70. Farias FH, Zeng R, Johnson GS, et al. A truncating mutation in ATP13A2 is responsible for adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers. Neurobiol Dis 2011; 42468-474.
71. Dick KJ, Eckhardt M, Paisan-Ruiz C, et al. Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum Mutat 2010; 31: E1251-E1260.
72. Edvardson S, Hama H, Shaag A, et al. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am J Hum Genet 2008; 83: 643-648.
73. Garone C, Pippucci T, Cordelli DM, et al. FA2H-related disorders: a novel c.270+3A>T splice-site mutation leads to a complex neurodegenerative phenotype. Dev Med Child Neurol 2011; 53: 958-961.
74. Bras J, Singleton A, Cookson MR, et al. Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 2008; 275: 5767-5773.
75. Hourani R, El-Hajj T, Barada WH, et al. MR imaging findings in autosomal recessive hereditary spastic paraplegia. AJNR Am J Neuroradiol 2009; 30: 936-940.
76. Kang SY, Lee MH, Lee SK, et al. Levodopa-responsive parkinsonism in hereditary spastic paraplegia with thin corpus callosum. Parkinsonism Relat Disord 2004; 10: 425-427.
77. Micheli F, Cersosimo MG, Zuniga RC. Hereditary spastic paraplegia associated with dopa-responsive parkinsonism. Mov Disord 2006; 21: 716-717.
78. Schicks J, Synofzik M, Petrusson H, Bauer P, Schöls L. Juvenile parkinsonism due to a novel SPG15 mutation. Mov Disord 2010; 25( Suppl 2): S524.
79. Anheim M, Lagier-Tourenne C, Stevanin G, et al. SPG11 spastic paraplegia. A new cause of juvenile parkinsonism. J Neurol 2009; 256: 104-108.
80. White KD, Ince PG, Lusher M, et al. Clinical and pathologic findings in hereditary spastic paraparesis with spastin mutation. Neurology 2000; 55: 89-94.
81. Potter KA, Kern MJ, Fullbright G, et al. Central nervous system dysfunction in a mouse model of Fa2h deficiency. Glia 2011; 59: 1009-1021.
82. McNeill A, Pandolfo M, Kuhn J, et al. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008; 60: 200-205.
83. Chinnery PF, Crompton DE, Birchall D, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007; 130: 110-119.
84. Chinnery PF. Neuroferritinopathy. In: Pagon RA, Bird TD, Dolan CR, Stephens K, eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993-2005.
85. Chinnery PF, Curtis AR, Fey C, et al. Neuroferritinopathy in a French family with late onset dominant dystonia. J Med Genet 2003; 40: e69.
86. Kubota A, Hida A, Ichikawa Y, et al. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov Disord 2009; 24: 441-445.
87. McNeill A, Birchall D, Hayflick SJ, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70: 1614-1619.
88. Hautot D, Pankhurst QA, Morris CM, et al. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. Biochim Biophys Acta 2007; 1772: 21-25.
89. Mancuso M, Davidzon G, Kurlan RM, et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol 2005; 64: 280-294.
90. Deng X, Vidal R, Englander EW. Accumulation of oxidative DNA damage in brain mitochondria in mouse model of hereditary ferritinopathy. Neurosci Lett 2010; 479: 44-48.
91. Kruer M, Gregory A, Hogarth P, Hayflick S. Static encephalopathy of childhood with neurodegeneration in adulthood (SENDA syndrome): a novel neurodegneration with brain iron accumulation (NBIA) phenotype [correspondence]. 2009. Abstract.
92. Hartig MB, Iuso A, Hempel M, et al. Identification of a second major locus for neurodegeneration with brain iron accumulation. Presented at the American Society of Human Genetics 59th Annual Meeting, Honolulu, 2009.
93. Brueggemann N, Wuerfel JT, Petersen D, et al. Idiopathic NBIA-clinical spectrum and transcranial sonography findings. Eur J Neurol 2011; 18: e58-e59.
94. Waldvogel D, van GP, Hallett M. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol 1999; 46: 123-125.
95. Levy M, Turtzo C, Llinas RH. Superficial siderosis: a case report and review of the literature. Nat Clin Pract Neurol 2007; 3: 54-58.
96. Chang MH, Hung WL, Liao YC, et al. Eye of the tiger-like MRI in parkinsonian variant of multiple system atrophy. J Neural Transm 2009; 116: 861-866.
97. Davie CA, Barker GJ, Machado C, et al. Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 1997; 12: 767-771.
98. Molinuevo JL, Munoz E, Valldeoriola F, et al. The eye of the tiger sign in cortical-basal ganglionic degeneration. Mov Disord 1999; 14: 169-171.
99. Santillo AF, Skoglund L, Lindau M, et al. Frontotemporal dementia-amyotrophic lateral sclerosis complex is simulated by neurodegeneration with brain iron accumulation. Alzheimer Dis Assoc Disord 2009; 23: 298-300.
100. Schwarz J, Weis S, Kraft E, et al. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996; 60: 98-101.
101. Schneider SA, Hardy J, Bhatia KP. Iron Accumulation in syndromes of neurodegeneration with brain accumulation-causative or consequential? J Neurol Neurosurg Psychiatry 2009; 80: 589-590.
102. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev 2008; 4: 616.
103. Birbes H, El Bawabb S, Obeid LM, Hannun YA. Mitochondria and ceramide: intertwined roles in regulation of apoptosis. Advan Enzyme Regul 2002; 42: 113-129.
104. Zorzi G, Zibordi F, Chiapparini L, et al. Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord 2011; 26: 1755-1759.
105. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 2007; 30: 317-337.
106. King MW. Accessed June 2011.
107. Eiberg H, Hansen L, Korbo L, et al. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Clin Genet 2011 [Epub ahead of print] Accessed June 2011.